Self-Contained Laboratory Homogenizer Prepares Injectable Drugs

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-10-02-2015
Volume 38
Issue 10
Pages: 14

GEA’s Pony NS2006L is a self-contained, high-pressure laboratory and pilot plant homogenizer for product development of advanced fluid applications.

GEA’s Pony NS2006L is a self-contained, high-pressure laboratory and pilot plant homogenizer for product development of advanced fluid applications, including nanoparticles, nanodispersions, nanoemulsions, and cell dispersions. The homogenizers can reduce particle sizes down to nanometer range for the preparation of injectable drugs.

The homogenizer is designed for continuous operation up to 1500 bar. The sanitary design is suited for clean-in-place and sterilization-in-place. The Pony NS2006L achieves the same results as larger size homogenizers, and its compact design allows easy installation with simple operation and quick maintenance. It is also suitable for viscous products.

GEAwww.gea.com
 

Articles in this issue
Fig.1b-Graph-GZD_495forweb.jpg
Identifying Powder Properties that Define Process Performance
Connecting MES to Process Control
Connecting MES to Process Control
PHT1015_PackForum_NJMphoto_300forweb.jpg
Parenteral Packaging Advances
Serialization Shake Out
Investigating Biologics
Advances in Fluorination Chemistry for API Synthesis
Advances in Fluorination Chemistry for API Synthesis
PT1015_ADD_artwork.jpg
Regulatory Considerations for Alcohol-Induced Dose Dumping of Oral Modified-Release Formulations
BP1015_Perspectives_Figure1-New-1444064165242.jpg
Small-Molecule API CMOs Are Thriving
NETZSCH_Alpha_22_225.jpg
Modular Platform for Agitator Bead Mill Optimizes Grinding
GEA_Pony-2006A2_225.jpg
Self-Contained Laboratory Homogenizer Prepares Injectable Drugs
Mitos_System-2_225.jpg
Microfluidics Systems Designed for Flow-Chemistry Experiments
Ross-SysCon-225.jpg
Control Systems
Till-Alice120-New-1444331636184.jpg
Evolving to Meet Industry Changes
Stretching Product Value through Reformulation Strategies
Stretching Product Value through Reformulation Strategies
Characterization and Formulation Screening of mAb and ADCs by High-Throughput DLS
Characterization and Formulation Screening of mAb and ADCs by High-Throughput DLS
Recent Videos
Behind the Headlines episode 6
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Alentis Therapeutics to Advance Anti-Claudin-1 ADCs to Treat Solid Tumors on $181.4 Million Financing

Feliza Mirasol
November 19th 2024
Article

Financing from OrbiMed, Novo Holdings, Jeito Capital, and others will enable Alentis Therapeutics to advance its pipeline of Claudin-1-targeted ADCs for treating solid tumors.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Newly Opened Innovation Center in New Jersey Gives Avantor Advantage in Solving Life Sciences Challenges

Feliza Mirasol
November 15th 2024
Article

Avantor's newly launched expanded Innovation Center in Bridgewater, NJ, is designed for integrated workflows and features purpose-built collaboration spaces.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Merck and Ginkgo Bioworks’ Collaboration to Improve Biologics Manufacturing Has Reached Its First Milestone

Feliza Mirasol
November 13th 2024
Article

Under an ongoing partnership with Merck, known as MSD outside of the United States and Canada, Ginkgo Bioworks has achieved the first milestone in a project aimed at improving biologics production.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

TrakCel’s OCELLOS Platform Selected to Support Treatment Management of Five Upcoming Cell Therapy Products

Feliza Mirasol
November 13th 2024
Article

Manufacturers of five autologous or matched allogenic cell therapy products have selected TrakCel's IT platform, OCELLOS, to orchestrate the administration of these therapies, which are approved or expected to be approved in 2024.